Key Takeaways Cheniere Energy Q4 EPS missed estimates as margins fell despite 23% higher revenues.LNG's volumes lifted EBITDA by 30% to $2B; full-year 2026 DCF guidance is raised to $4.85B.LNG expanded buybacks to $10B and advanced Stage 3 trains and capacity plans.Cheniere Energy, Inc. (LNG) reported a fourth-quarter 2025 adjusted profit of $2.87 per share, which missed the Zacks Consensus Estimate of $3.83. The bottom line also decreased from the year-ago quarter’s level of $4.33, primarily due to lower t ...

More than 7 years of experience in equity analysis in LatAm. We provide our clients with in-depth research and insights to help them make informed investment decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relat ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alight, Inc. (NYSE: ALIT) resulting from allegations that Alight may have issued materially misleading business information to the investing public. So What: If you purchased Alight securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Goldman Sachs Stock Tests Key Support. A Breakdown Could Pressure the Market. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# All Eyes on Goldman Sachs as Key Support WobblesBy [Doug Busch]ShareResize---ReprintsIn this article[SPX][GS]Goldm ...

LONDON--(BUSINESS WIRE)-- #insurance--AM Best has maintained the under review with positive implications status for the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a†(Excellent) of Aspen Insurance UK Limited (United Kingdom), Aspen Bermuda Limited (Bermuda), Aspen American Insurance Company (Austin, TX) and Aspen Specialty Insurance Company (Bismarck, ND). Concurrently, AM Best has maintained under review with positive implications for the Long-Term ICR of "bbb†(G. ...

Key Takeaways Perrigo's Q4 EPS fell 17.2% to 77 cents as Infant Formula weakness hit sales and margins.PRGO guided All In 2026 sales down 1.5%-5.5% and EPS of $2.00-$2.30, below expectations.Perrigo will restructure into Self Care, Specialty Care and Infant Formula segments in 2026.Perrigo (PRGO) reported adjusted earnings per share (EPS) of 77 cents for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 80 cents. The reported figure decreased 17.2% year over year, primarily due to hea ...

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...